Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (TSE:APS)
TSX:APS
APS Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.02 - C$23.70
Previous CloseN/A
Volume48.76K
Average Volume (3M)9.10K
Market Cap
$4.29M
Enterprise ValueC$15.80M
Total Cash (Recent Filing)$4.70M
Total Debt (Recent Filing)$8.98M
Price to Earnings (P/E)―
Beta-1.35
Next Earnings
Aug 07, 2025EPS Estimate
-3.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.60
Shares Outstanding2,552,429
10 Day Avg. Volume5,914
30 Day Avg. Volume9,095
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap3.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-133.91
Enterprise Value/Ebitda-0.76
Forecast
1Y Price Target
$8.22Price Target Upside389.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical ProgressAptose has made progress in progressing tuspetinib in the clinic, including initiating and reporting early safety and efficacy data from TUSCANY, a Phase 1/2 triplet combo study in newly diagnosed acute myeloid leukemia.
Financial StabilityThe company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.
Treatment EfficacyTwo FLT3-WT patients achieved complete remissions by the end of Cycle 1, with a patient having biallelic TP53 mutations and a complex karyotype achieving a complete remission.
Bears Say
Funding NeedsAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.
Aptose Biosciences News
APS FAQ
What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was C$1.02 and its highest was C$23.70 in the past 12 months.
What is Aptose Biosciences’s market cap?
Aptose Biosciences’s market cap is $4.29M.
When is Aptose Biosciences’s upcoming earnings report date?
Aptose Biosciences’s upcoming earnings report date is Aug 07, 2025 which is in 2 days.
How were Aptose Biosciences’s earnings last quarter?
Aptose Biosciences released its earnings results on May 08, 2025. The company reported -C$3.602 earnings per share for the quarter, beating the consensus estimate of -C$3.684 by C$0.083.
Is Aptose Biosciences overvalued?
According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued.
Does Aptose Biosciences pay dividends?
Aptose Biosciences does not currently pay dividends.
What is Aptose Biosciences’s EPS estimate?
Aptose Biosciences’s EPS estimate is -3.78.
How many shares outstanding does Aptose Biosciences have?
Aptose Biosciences has 2,552,429 shares outstanding.
What happened to Aptose Biosciences’s price movement after its last earnings report?
Aptose Biosciences reported an EPS of -C$3.602 in its last earnings report, beating expectations of -C$3.684. Following the earnings report the stock price went up 3.256%.
Which hedge fund is a major shareholder of Aptose Biosciences?
Currently, no hedge funds are holding shares in TSE:APS
Company Description
Aptose Biosciences
Aptose Biosciences Inc. (APS) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of highly differentiated therapeutics addressing unmet medical needs in oncology. The company specializes in developing targeted therapies for the treatment of hematologic malignancies and other life-threatening diseases. Aptose leverages a deep understanding of cancer biology to develop innovative small molecule cancer drugs.
Technical Analysis
Ownership Overview
24.03% Insiders
<0.01%
Mutual Funds
0.16% Other Institutional Investors
75.81% Public Companies and Individual Investors
Options Prices
Currently, No data available
---